PubRank

S Negoro

Author PubWeight™ 123.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2006 3.12
2 A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992 2.58
3 Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996 2.31
4 Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature 1984 2.29
5 Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008 2.19
6 Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 2009 2.14
7 Structure of a beta-galactosidase gene of Bacillus stearothermophilus. J Bacteriol 1986 1.99
8 6-Aminohexanoic acid cyclic dimer hydrolase. A new cyclic amide hydrolase produced by Achromobacter guttatus KI74. Eur J Biochem 1977 1.91
9 Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003 1.75
10 Plasmid control of 6-aminohexanoic acid cyclic dimer degradation enzymes of Flavobacterium sp. KI72. J Bacteriol 1980 1.55
11 Sequence and properties of beta-xylosidase from Bacillus pumilus IPO. Contradiction of the previous nucleotide sequence. Eur J Biochem 1991 1.55
12 Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci U S A 2000 1.55
13 Plasmid-determined enzymatic degradation of nylon oligomers. J Bacteriol 1983 1.50
14 Isopeptidase: a novel eukaryotic enzyme that cleaves isopeptide bonds. Proc Natl Acad Sci U S A 1982 1.47
15 Molecular cloning of the genes for xylan degradation of Bacillus pumilus and their expression in Escherichia coli. Mol Gen Genet 1983 1.45
16 Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 2000 1.42
17 Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996 1.41
18 Mutant fibronectin gene in skin fibroblasts of sclerotic lesions from patients with progressive systemic sclerosis. Arthritis Rheum 1989 1.41
19 CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992 1.40
20 High homology between 6-aminohexanoate-cyclic-dimer hydrolases of Flavobacterium and Pseudomonas strains. J Bacteriol 1989 1.29
21 A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 1991 1.27
22 Molecular basis of isozyme formation of beta-galactosidases in Bacillus stearothermophilus: isolation of two beta-galactosidase genes, bgaA and bgaB. J Bacteriol 1984 1.24
23 Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol 2000 1.23
24 Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect Immun 1980 1.18
25 High Production of Thermostable beta-Galactosidase of Bacillus stearothermophilus in Bacillus subtilis. Appl Environ Microbiol 1985 1.18
26 Plasmid dependence of Pseudomonas sp. strain NK87 enzymes that degrade 6-aminohexanoate-cyclic dimer. J Bacteriol 1989 1.16
27 Age-related changes of heat shock protein gene transcription in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 1988 1.13
28 A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013 1.12
29 Solubility of artificial proteins with random sequences. FEBS Lett 1996 1.11
30 Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheum 1987 1.10
31 Nylon oligomer degradation gene, nylC, on plasmid pOAD2 from a Flavobacterium strain encodes endo-type 6-aminohexanoate oligomer hydrolase: purification and characterization of the nylC gene product. Appl Environ Microbiol 1993 1.10
32 Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005 1.08
33 Thermostable peroxidase from Bacillus stearothermophilus. J Gen Microbiol 1988 1.05
34 CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992 1.04
35 Cloning, nucleotide sequence, and expression in Escherichia coli of the Bacillus stearothermophilus peroxidase gene (perA). J Bacteriol 1989 1.04
36 Construction of hybrid genes of 6-aminohexanoic acid-oligomer hydrolase and its analogous enzyme. Estimation of the intramolecular regions important for the enzyme evolution. J Biol Chem 1984 1.03
37 Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009 1.03
38 Structure and properties of malic enzyme from Bacillus stearothermophilus. J Biol Chem 1989 1.03
39 A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 1998 1.02
40 A plasmid encoding enzymes for nylon oligomer degradation: nucleotide sequence and analysis of pOAD2. Microbiology 1995 1.01
41 Insertion sequence IS6100 on plasmid pOAD2, which degrades nylon oligomers. J Bacteriol 1994 0.98
42 Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway. J Biol Chem 2001 0.98
43 Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer. Cancer 1994 0.98
44 Cloning, nucleotide sequences, and enzymatic properties of glucose dehydrogenase isozymes from Bacillus megaterium IAM1030. J Bacteriol 1992 0.97
45 Stability-increasing mutants of glucose dehydrogenase from Bacillus megaterium IWG3. J Biol Chem 1989 0.96
46 Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 2007 0.96
47 Protooncogene expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus as an indicator of the disease activity. Clin Immunol Immunopathol 1987 0.95
48 Mechanisms of age-related decline in antigen-specific T cell proliferative response: IL-2 receptor expression and recombinant IL-2 induced proliferative response of purified Tac-positive T cells. Mech Ageing Dev 1986 0.95
49 Clinicopathological characterization of cardiac free wall rupture in patients with acute myocardial infarction: difference between early and late phase rupture. Int J Cardiol 1994 0.95
50 Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993 0.93
51 DNA-DNA hybridization analysis of nylon oligomer-degradative plasmid pOAD2: identification of the DNA region analogous to the nylon oligomer degradation gene. J Bacteriol 1984 0.93
52 Monoclonal antibody SN2 defining a human T cell leukemia-associated cell surface glycoprotein. J Immunol 1984 0.92
53 Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995 0.91
54 Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998 0.91
55 Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1997 0.91
56 gp130-Dependent signalling pathway is not enhanced in gp130 transgenic heart after LIF stimulation. Cytokine 2000 0.90
57 Characterization of the 6-aminohexanoate-dimer hydrolase from Pseudomonas sp. NK87. J Gen Microbiol 1993 0.88
58 A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 2006 0.88
59 Functional interleukin 2 receptors on B cells lacking Tac antigens. Eur J Immunol 1987 0.88
60 Novel receptor-mediated internalization of interleukin 2 in B cells. J Immunol 1988 0.87
61 Amino acid alterations essential for increasing the catalytic activity of the nylon-oligomer-degradation enzyme of Flavobacterium sp. Eur J Biochem 1991 0.87
62 Regulatory mechanism of autoantibody production in mice to bromelin-treated isologous red blood cells. Immunology 1979 0.87
63 Monoclonal antibody that defines a unique human T-cell leukemia antigen. Proc Natl Acad Sci U S A 1983 0.87
64 Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999 0.87
65 Heat-shock protein synthesis by human peripheral mononuclear cells from SLE patients. Biochem Biophys Res Commun 1987 0.86
66 Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 1998 0.86
67 [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]. Gan To Kagaku Ryoho 1987 0.86
68 Isolation and characterization of the murine cardiotrophin-1 gene: expression and norepinephrine-induced transcriptional activation. J Mol Cell Cardiol 2000 0.86
69 Prognostic factors in elderly patients with unresectable non-small cell lung cancer. Anticancer Res 2001 0.86
70 Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 2003 0.86
71 Interleukin 2 functions through novel interleukin 2 binding molecules in T cells. J Immunol 1988 0.85
72 Several new monoclonal antibodies directed to human T-cell leukemia antigens. Cancer Res 1982 0.84
73 CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997 0.84
74 Application of N-terminally truncated DNA polymerase from Thermus thermophilus (delta Tth polymerase) to DNA sequencing and polymerase chain reactions: comparative study of delta Tth and wild-type Tth polymerases. DNA Res 1996 0.84
75 Emergence of nylon oligomer degradation enzymes in Pseudomonas aeruginosa PAO through experimental evolution. Appl Environ Microbiol 1995 0.83
76 Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999 0.83
77 Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000 0.83
78 Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998 0.83
79 A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 1991 0.83
80 [Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer]. Gan To Kagaku Ryoho 1994 0.82
81 Age-related changes of the function of T cell subsets: predominant defect of the proliferative response in CD8 positive T cell subset in aged persons. Mech Ageing Dev 1987 0.82
82 Human T cell leukemia antigens on the cell membranes: purification molecular characterization, and preparation of specific antisera. J Immunol 1981 0.81
83 Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001 0.81
84 Properties of artificial proteins with random sequences. Ann N Y Acad Sci 1998 0.80
85 Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer 2002 0.80
86 Strong, specific anti-human leukemia antisera prepared with the use of purified cell membrane antigen. Cancer Res 1981 0.80
87 Decreased expression of interleukin-2 binding molecules (p70/75) in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989 0.80
88 Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann Oncol 1996 0.80
89 Methylation of c-myc gene changes in human lymphoproliferative diseases. Biosci Rep 1987 0.80
90 Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study. Am J Clin Oncol 1992 0.79
91 Demonstration of functional immaturity of signal transduction pathways in human cord T cells. Cell Immunol 1989 0.79
92 Alternating non-cross resistant chemotherapy for small cell lung cancer. Jpn J Clin Oncol 1986 0.78
93 Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 2000 0.78
94 Cell surface membrane antigen present on neuroblastoma cells but not fetal neuroblasts recognized by a monoclonal antibody (KP-NAC8). Cancer Res 1987 0.78
95 Angiotensin II interferes with leukemia inhibitory factor-induced STAT3 activation in cardiac myocytes. Biochem Biophys Res Commun 1998 0.78
96 Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation. J Clin Invest 1988 0.78
97 [A phase I study of weekly administration of CPT-11 in lung cancer]. Gan To Kagaku Ryoho 1990 0.78
98 [Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)]. Gan To Kagaku Ryoho 1996 0.78
99 Phase I study of combined radiation, hyperthermia and intra-arterial carboplatin for local recurrence of cervical cancer. Ann Oncol 2003 0.78
100 Isolation and properties of mannans from Alternaria kikuchiana Tanaka and Alternaria zinniae. Jpn J Microbiol 1971 0.77
101 Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995 0.77
102 Age-related changes of expression of IL-2 receptor subunits and kinetics of IL-2 internalization in T cells after mitogenic stimulation. Mech Ageing Dev 1988 0.77
103 [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer]. Gan To Kagaku Ryoho 1987 0.77
104 Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001 0.77
105 Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 1990 0.77
106 Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient. Eur J Pediatr 1989 0.77
107 Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. J Natl Cancer Inst 1991 0.77
108 Age-associated changes in proliferative and differentiative response of human B cells and production of T cell-derived factors regulating B cell functions. Mech Ageing Dev 1987 0.77
109 Photodynamic Therapy With YAG-OPO Laser for Early Stage Lung Cancer. Diagn Ther Endosc 1997 0.77
110 Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 2004 0.77
111 [A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group]. Gan To Kagaku Ryoho 2000 0.77
112 A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer. Cancer 1991 0.77
113 Determinants of myelosuppression in the treatment of non-small cell lung cancer with cisplatin-containing chemotherapy. Jpn J Cancer Res 1996 0.77
114 Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. Breast Cancer Res Treat 2014 0.76
115 Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 1991 0.75
116 Induction of persistent autoimmune haemolytic anaemia in mice by combined use of rat erythrocyte preimmunization and chronic GVHR. Immunology 1985 0.75
117 C-myc gene binding factors in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1989 0.75
118 Nuclear phosphotyrosyl-protein with DNA-binding ability in peripheral blood mononuclear cells from systemic lupus erythematosus patients. Clin Exp Immunol 1989 0.75
119 Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue. Br J Cancer 1998 0.75
120 New antigenic determinant common to human thymus leukaemia-associated antigens and common acute lymphoblastic leukaemia antigen. Clin Exp Immunol 1981 0.75
121 Age-related changes of proliferative response, kinetics of expression of protooncogenes after the mitogenic stimulation and methylation level of the protooncogene in purified human lymphocyte subsets. Mech Ageing Dev 1988 0.75
122 The effect of taurine on age-related immune decline in mice: the effect of taurine on T cell and B cell proliferative response under costimulation with ionomycin and phorbol myristate acetate. Mech Ageing Dev 1990 0.75
123 Irinotecan in small-cell lung cancer--Japanese trials. Oncology (Williston Park) 2000 0.75
124 [CD antigens and the differentiation of human lymphocytes]. Hum Cell 1988 0.75
125 c-fos expression in human skin fibroblasts by reperfusion after oxygen deficiency: a recovery change of human skin fibroblasts after oxygen deficiency stress. Biochem Biophys Res Commun 1987 0.75
126 [Age-related functional and proportional changes in human lymphocytes: clinical significance as indicators for immunosenescence]. Nihon Ronen Igakkai Zasshi 1987 0.75
127 Redevelopment of small-cell lung cancer nine years after the start of therapy. A case report and review of the literature. Am J Clin Oncol 1991 0.75
128 Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer. Jpn J Clin Oncol 1996 0.75
129 Postinflammatory bronchiectatic cavity observed by fibreoptic bronchoscopy. Eur Respir J 1994 0.75
130 [Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin]. Gan To Kagaku Ryoho 1997 0.75
131 [Phase II study of cis-dichlorodiammineplatinum (II) for non-small cell lung cancer]. Gan To Kagaku Ryoho 1985 0.75
132 [Combination chemotherapy with peplomycin and carboquone (esquinon) for squamous cell carcinoma of the lung]. Gan To Kagaku Ryoho 1982 0.75
133 [Trends in immunology]. Nihon Rinsho 1983 0.75
134 [Current results of chemotherapy in non-small cell lung cancer]. Nihon Kyobu Shikkan Gakkai Zasshi 1990 0.75
135 Recurrent mucocutaneous lymphocytic infiltration possibly associated with Epstein-Barr virus infection. Dermatologica 1991 0.75
136 Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up. Cancer 1990 0.75
137 The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Int J Gynecol Cancer 2002 0.75
138 Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994 0.75
139 5-Azacytidine induced inhibition of mitogenic response by agents that activate or augment activation of human peripheral blood T lymphocytes. Biochem Biophys Res Commun 1988 0.75
140 [Response and pharmacokinetics of cisplatin instilled into the pleural cavity]. Gan To Kagaku Ryoho 1985 0.75
141 Immunopharmacological actions of an extract isolated from inflamed skin of rabbits inoculated with Vaccinia virus (Neurotropin)--II. Restorative effect on immune responses through the recovery of IL-2 production in aging mice. Int J Immunopharmacol 1989 0.75
142 Altered expression of cell surface membrane antigens in a common acute lymphoblastic leukemia-associated antigen-expressing neuroblastoma cell line (SJ-N-CG) with morphological differentiation. Cancer Res 1985 0.75
143 Restorative effect of neurotropin on maturation of bone marrow cells to IL-2-producing T-cells in aging BALB/c mice. Int J Immunopharmacol 1991 0.75
144 [Chemotherapy of small cell lung cancer]. Gan To Kagaku Ryoho 1988 0.75
145 [Treatment of metastatic renal cell carcinoma with human lymphoblastoid interferon]. Nihon Gan Chiryo Gakkai Shi 1987 0.75
146 [Immunosuppressive effects of rifampicin (author's transl)]. Kekkaku 1976 0.75
147 Weekly dose-intensive chemotherapy in patients with small-cell lung cancer: a pilot study. Am J Clin Oncol 1992 0.75
148 Autoantibody to human c-myc oncogene product in autoimmune patients' sera. Int Arch Allergy Appl Immunol 1988 0.75
149 Three-year disease-free survivors of small cell lung cancer treated with combination chemotherapy with or without chest irradiation. Eur J Cancer Clin Oncol 1989 0.75
150 [Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method]. Gan To Kagaku Ryoho 1988 0.75
151 [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group]. Gan To Kagaku Ryoho 1995 0.75
152 Regulation of beta-endorphin receptor expression in mouse spleen cells with Con A and rIL-2. Int J Immunopharmacol 1992 0.75
153 [Studies on an appropriate intra thoracic administration of cisplatin and sodium thiosulfate in malignant pleural effusion]. Gan To Kagaku Ryoho 1988 0.75
154 Right ventricular cardiomyopathy accompanied by protein-losing enteropathy and chylous effusion. Jpn Circ J 2001 0.75
155 Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan. Cancer 1996 0.75
156 [High-dose Tegafur (FT) for primary lung cancer: a phase I trial]. Gan To Kagaku Ryoho 1991 0.75
157 [Beta and alpha adrenergic receptor density on cellular components of peripheral blood in patients with bronchial asthma. 1. Relationship between receptor density and airway hypersensitivity]. Arerugi 1986 0.75
158 Carcinoembryonic antigen (CEA) levels in pleural effusions and sera of lung cancer patients. Jpn J Clin Oncol 1984 0.75
159 [Age-associated changes in immune functions]. Rinsho Byori 1988 0.75
160 [Phase II studies of a single agent and a cis-platinum-based two-drug combination in patients with non-small cell lung cancer]. Gan To Kagaku Ryoho 1988 0.75
161 Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method. Arzneimittelforschung 1989 0.75
162 [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy]. Gan To Kagaku Ryoho 1990 0.75
163 [Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994]. Gan To Kagaku Ryoho 1996 0.75
164 [Local application of anti-cancer drugs for the treatment of malignant pleural and pericardial effusion]. Gan To Kagaku Ryoho 1984 0.75
165 [The characteristic changes of immune function with aging]. Kekkaku 1989 0.75
166 Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule. Clin Cancer Res 2000 0.75
167 [Prognosis of small cell lung cancer with ipsilateral pleural effusion]. Nihon Kyobu Shikkan Gakkai Zasshi 1992 0.75
168 Lupus-related transcript homologous to Abelson-murine leukemia virus. Biochem Biophys Res Commun 1988 0.75
169 [Recent trends in autoimmune disease research]. Nihon Rinsho 1988 0.75
170 Proto-oncogene expression and nuclear factor specifically bound to c-myc gene in peripheral blood mononuclear cells from progressive systemic sclerosis patients as the indicator of clinical activity. J Clin Lab Immunol 1988 0.75
171 [Conditions suitable for chemotherapy of lung cancer]. Gan No Rinsho 1983 0.75
172 [Enzymes and genetic informations of hydrolases active on nylon oligomer, unnatural substrates (author's transl)]. Tanpakushitsu Kakusan Koso 1982 0.75
173 [Dose intensity chemotherapy in lung cancer]. Gan To Kagaku Ryoho 1990 0.75
174 Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule. Invest New Drugs 1999 0.75
175 Combination therapy with bestatin in inoperable lung cancer. A randomized trial. Acta Oncol 1990 0.75
176 [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group]. Gan To Kagaku Ryoho 2000 0.75
177 [The significance of CA-50, SLX and ST-439 in lung cancer]. Nihon Kyobu Shikkan Gakkai Zasshi 1991 0.75
178 Changes in inducible nuclear factors with specific binding ability to c-myc gene fragments in peripheral blood mononuclear cells from systemic lupus erythematosus patients. J Clin Lab Immunol 1989 0.75
179 [Thoracoscopic pleural biopsy under local anesthesia using a 2 mm laparoscope]. Nihon Kokyuki Gakkai Zasshi 2000 0.75
180 [Treatment for brain metastasis from lung cancer in the era of radiosurgery]. No Shinkei Geka 2001 0.75
181 Interaction between activated VD3 and Ca channel blockers in patients undergoing hemodialysis. Int J Clin Pharmacol Ther 2007 0.75